Anna Maggie Weiss

Dr. Anna Maggie Weiss


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2021 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
AWAnna Maggie Weiss
Anna Maggie Weiss
JCJordan Campbell
Jordan Campbell
KBKarla V. Ballman
Karla V. Ballman
WSWilliam M. Sikov
William M. Sikov
LCLisa A. Carey
Lisa A. Carey
MGMehra Golshan
Mehra Golshan

1 October 2018 in The American Journal of Surgery
Verified
Journal Article
Closed access
AWAnna Maggie Weiss
Anna Maggie Weiss
RPRalitza Parina
Ralitza Parina
VTViridiana J. Tapia
Viridiana J. Tapia
DSDivya Sood
Divya Sood
KLKatherine C. Lee
Katherine C. Lee
SRSonia L. Ramamoorthy
Sonia L. Ramamoorthy

25 April 2019 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
AWAnna Maggie Weiss
Anna Maggie Weiss
HLHeather Lin
Heather Lin
GBGildy V. Babiera
Gildy V. Babiera
IBIsabelle Bedrosian
Isabelle Bedrosian
SSSimona F. Shaitelman
Simona F. Shaitelman
RHRosa F. Hwang
Rosa F. Hwang

1 August 2018 in Clinical Breast Cancer
Verified
Journal Article
Closed access
AWAnna Maggie Weiss
Anna Maggie Weiss
EMElizabeth A. Mittendorf
Elizabeth A. Mittendorf
SDSarah M. DeSnyder
Sarah M. DeSnyder
RHRosa F. Hwang
Rosa F. Hwang
VBVivian Bea
Vivian Bea
ACAbigail S. Caudle
Abigail S. Caudle

12 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
SNSujan Niraula
Sujan Niraula
AKAnjan Katel
Anjan Katel
ABAmit Barua
Amit Barua
AWAnna Maggie Weiss
Anna Maggie Weiss
MSMyla Strawderman
Myla Strawderman
ADAjay Dhakal
Ajay Dhakal
Breast augmentation is considered safe, but rare cases of breast implant-associated squamous cell carcinoma (BIA-SCC) have been reported. This study aimed to systematically review published cases of BIA-SCC, providing valuable clinical data. The review included 14 articles and 18 cases of BIA-SCC. An increasing trend in reported BIA-SCC cases was observed, with four cases in the 1990s and 14 cases since 2010. The mean age of affected patients was 56 years, and symptoms typically appeared around 21 years after breast augmentation. Silicone implants used in cosmetic procedures were most commonly associated with BIA-SCC. Implant removal was necessary in all cases, and some patients required a mastectomy. Treatment approaches varied, with the selective use of chemotherapy and/or radiotherapy. The estimated 6-month mortality rate was 11.1%, while the 12-month mortality rate was 23.8%. The estimated 6-month mortality rate should be cautiously interpreted due to the limited sample size. It appears lower than the rate reported by the American Society of Plastic Surgeons, without clear reasons for this discrepancy. This study highlights the importance of enhanced monitoring and information sharing to improve detection and management of BIA-SCC. Healthcare providers should maintain vigilance during the long-term follow-up of breast augmentation patients.

16 April 2018 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
AWAnna Maggie Weiss
Anna Maggie Weiss
SBSami Bashour
Sami Bashour
KHKenneth Hess
Kenneth Hess
ATAlastair M. Thompson
Alastair M. Thompson
NINuhad K. Ibrahim
Nuhad K. Ibrahim
Patients with breast cancer who have a pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) have improved survival. We hypothesize that once pCR has been achieved, there is no difference in subsequent postsurgical recurrence-free survival (RFS), whichever NACT regimen is used. Data from patients with breast cancer who achieved pCR after NACT between 1996 and 2011 were reviewed. RFS was estimated by the Kaplan-Meier method, and differences between groups were assessed using log-rank testing. Cox proportional hazards regression analysis adjusted for age, menopausal status, stage, grade, tumor subtype, and adjuvant endocrine HER2-targeted radiation treatment. Among 721 patients who achieved pCR after NACT, 157 (21.8%) were hormone receptor-positive (HR), 310 (43.3%) were HER2-amplified, and 236 (32.7%) were triple-negative; 292 (40.5%) were stage IIA, 153 (21.2%) were stage IIB, 78 (10.8%) were stage IIIA, 66 (9.2%) were stage IIIB, and 132 (18.3%) were stage IIIC. Most patients (367 [50.9%]) had been treated with adriamycin-based chemotherapy plus taxane (A + T), 56 (7.8%) without taxane (A no T), 227 (31.5%) with HER2-targeted therapy, and 71 (9.8%) provider choice. Median follow-up was 7.1 years. Adjuvant chemotherapy was employed in 196 (27%) patients, adjuvant endocrine in 261 (36%), and adjuvant radiation in the majority (559 [77.5%]). There was no statistically significant difference in RFS by NACT group. Adjusted RFS hazard ratios, comparing each treatment with the reference group A + T, were 1.25 (95% CI 0.47–3.35) for A no T, 0.90 (95% CI 0.37–2.20) for HER2-targeted therapy, and 1.28 (95% CI 0.55–2.98) for provider choice. These data suggest that postsurgical RFS is not significantly influenced by the choice of NACT or cancer subtype among patients achieving pCR.